Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | terminated | Phase 3 | 1,594 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 10, 2026 | clinicaltrials |
| NCT01272609 | Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel | terminated | Phase 3 | 25 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 17, 2026 |
| clinicaltrials |
| NCT04695977 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | terminated | Phase 2 / Phase 3 | 20 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05002569 | A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma(RELATIVITY-098) | terminated | Phase 3 | 1,093 | Bristol-Myers SquibbINDUSTRY | 25 | Jan 8, 2026 | clinicaltrials |
| NCT01546571 | Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients(MAVIS) | terminated | Phase 3 | 504 | Polynoma LLCINDUSTRY | 2 | Oct 24, 2025 | clinicaltrials |
| NCT02967692 | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma(COMBI-i) | terminated | Phase 3 | 568 | Novartis PharmaceuticalsINDUSTRY | 29 | Sep 18, 2025 | clinicaltrials |
| NCT00087776 | Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma | terminated | Phase 3 | 393 | American Regent, Inc.INDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04901988 | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION(DETECTION) | terminated | Phase 2 / Phase 3 | 8 | The Christie NHS Foundation TrustOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03233828 | Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2(IL-2) | terminated | Phase 3 | 1 | Carman GiacomantonioOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence(PIVOT-12) | terminated | Phase 3 | 765 | Nektar TherapeuticsINDUSTRY | 17 | Apr 21, 2023 | clinicaltrials |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma(MASTERKEY-265) | terminated | Phase 3 | 713 | AmgenINDUSTRY | 21 | Nov 14, 2022 | clinicaltrials |
| NCT03445533 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | terminated | Phase 3 | 481 | Idera Pharmaceuticals, Inc.INDUSTRY | 11 | Nov 8, 2022 | clinicaltrials |
| NCT02288897 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | terminated | Phase 3 | 20 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 5 | Jan 19, 2022 | clinicaltrials |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | terminated | Phase 3 | 1,351 | GlaxoSmithKlineINDUSTRY | 32 | Mar 5, 2021 | clinicaltrials |
| NCT01280565 | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit | terminated | Phase 3 | 134 | AB ScienceINDUSTRY | 7 | Nov 5, 2020 | clinicaltrials |
| NCT03552549 | SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) | terminated | Phase 2 / Phase 3 | 126 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 24, 2019 | clinicaltrials |
| NCT01875653 | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | terminated | Phase 3 | 4 | Lisata Therapeutics, Inc.INDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT00540969 | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases | terminated | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT01006252 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma(SUMMIT-1) | terminated | Phase 3 | 336 | Eli Lilly and CompanyINDUSTRY | 18 | Jul 17, 2018 | clinicaltrials |
| NCT01264874 | MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients(MelaViD) | terminated | Phase 3 | 150 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT00522834 | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | terminated | Phase 3 | 630 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Mar 4, 2014 | clinicaltrials |
| NCT01013623 | Stage IV Surgery Versus Best Medical Therapy(STG4SURG) | terminated | Phase 3 | 12 | Saint John's Cancer InstituteOTHER | 5 | Sep 26, 2012 | clinicaltrials |
| NCT00020839 | Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain | terminated | Phase 3 | 23 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Sep 24, 2012 | clinicaltrials |
| NCT00036816 | Vaccine Therapy in Treating Patients With Melanoma of the Eye | terminated | Phase 3 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Sep 24, 2012 | clinicaltrials |
| NCT00110123 | Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma | terminated | Phase 3 | 171 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 24, 2012 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials